Search

Your search keyword '"Jones PL"' showing total 54 results

Search Constraints

Start Over You searched for: Author "Jones PL" Remove constraint Author: "Jones PL" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
54 results on '"Jones PL"'

Search Results

2. Have a Little Heart (or Not): Highly Minimized Skeletal Muscle Regulatory Cassettes with Low or No Activity in the Heart.

3. Muscle eosinophilia is a hallmark of chronic disease in facioscapulohumeral muscular dystrophy.

4. Regional and bilateral MRI and gene signatures in facioscapulohumeral dystrophy: implications for clinical trial design and mechanisms of disease progression.

5. Inter-colony variation in predation, mercury burden and adult survival in a declining seabird.

6. Compound-Specific Behavioral and Enzymatic Resistance to Toxic Milkweed Cardenolides in a Generalist Bumblebee Pollinator.

7. Human DUX4 and porcine DUXC activate similar early embryonic programs in pig muscle cells: implications for preclinical models of FSHD.

8. Validation of the association between MRI and gene signatures in facioscapulohumeral dystrophy muscle: implications for clinical trial design.

9. Factors influencing mercury levels in Leach's storm-petrels at northwest Atlantic colonies.

10. Female and male Leach's Storm Petrels ( Hydrobates leucorhous ) pursue different foraging strategies during the incubation period.

12. Human iPSC-derived astrocytes generated from donors with globoid cell leukodystrophy display phenotypes associated with disease.

13. Long-term memory in frog-eating bats.

14. FSHD Therapeutic Strategies: What Will It Take to Get to Clinic?

15. Cross-sectional Neuromuscular Phenotyping Study of Patients With Arhinia With SMCHD1 Variants.

16. Identification of Serum Interleukin 6 Levels as a Disease Severity Biomarker in Facioscapulohumeral Muscular Dystrophy.

17. Precise Epigenetic Analysis Using Targeted Bisulfite Genomic Sequencing Distinguishes FSHD1, FSHD2, and Healthy Subjects.

18. Identification of candidate miRNA biomarkers for facioscapulohumeral muscular dystrophy using DUX4-based mouse models.

20. Targeted epigenetic repression by CRISPR/dSaCas9 suppresses pathogenic DUX4-fl expression in FSHD.

21. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.

22. Interpretation of the Epigenetic Signature of Facioscapulohumeral Muscular Dystrophy in Light of Genotype-Phenotype Studies.

23. Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy.

24. Accelerating implementation of research in Learning Health Systems: Lessons learned from VA Health Services Research and NCATS Clinical Science Translation Award programs.

25. SGLT2 Inhibitors and the Risk of Hospitalization for Fournier's Gangrene: A Nested Case-Control Study.

26. Muscle xenografts reproduce key molecular features of facioscapulohumeral muscular dystrophy.

27. The Good, The Bad, and The Unexpected: Roles of DUX4 in Health and Disease.

28. The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy.

29. Cardenolide Intake, Sequestration, and Excretion by the Monarch Butterfly along Gradients of Plant Toxicity and Larval Ontogeny.

30. The physiology of saltwater acclimation in large juvenile Atlantic salmon Salmo salar.

31. Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy.

32. Social Learning Strategies: Bridge-Building between Fields.

34. A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy.

35. CRISPR/Cas9 knockouts reveal genetic interaction between strain-transcendent erythrocyte determinants of Plasmodium falciparum invasion.

36. Corrigendum: SMCHD1 mutations associated with a rare muscular dystrophy can also cause isolated arhinia and Bosma arhinia microphthalmia syndrome.

37. Large family cohorts of lymphoblastoid cells provide a new cellular model for investigating facioscapulohumeral muscular dystrophy.

38. SMCHD1 mutations associated with a rare muscular dystrophy can also cause isolated arhinia and Bosma arhinia microphthalmia syndrome.

39. Learning in Insect Pollinators and Herbivores.

40. Consequences of toxic secondary compounds in nectar for mutualist bees and antagonist butterflies.

41. Scalpel or Straitjacket: CRISPR/Cas9 Approaches for Muscular Dystrophies.

42. Transgenic Drosophila for Investigating DUX4 and FRG1, Two Genes Associated with Facioscapulohumeral Muscular Dystrophy (FSHD).

43. CRISPR/dCas9-mediated Transcriptional Inhibition Ameliorates the Epigenetic Dysregulation at D4Z4 and Represses DUX4-fl in FSH Muscular Dystrophy.

44. Sensory-based niche partitioning in a multiple predator - multiple prey community.

45. Facioscapulohumeral muscular dystrophy as a model for epigenetic regulation and disease.

46. Role played by Prx1-dependent extracellular matrix properties in vascular smooth muscle development in embryonic lungs.

47. Emerging preclinical animal models for FSHD.

48. Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy.

49. The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents.

Catalog

Books, media, physical & digital resources